Core Viewpoint - As of October 31, 2025, Kefu Medical (301087) closed at 43.71 yuan, down 4.35%, with a trading volume of 43,200 hands and a transaction amount of 192 million yuan [1] Financial Performance - For the first three quarters of 2025, Kefu Medical reported a main revenue of 2.398 billion yuan, a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% year-on-year [4] - In Q3 2025, the company achieved a single-quarter main revenue of 902 million yuan, a year-on-year increase of 30.72%, and a net profit of 92.83 million yuan, up 38.68% year-on-year [4] - The company's gross profit margin stands at 53.35%, with a net profit margin of 10.82% [4] Market Activity - On October 31, 2025, the net inflow of main funds was 2.0172 million yuan, accounting for 1.05% of the total transaction amount, while retail investors saw a net inflow of 10.5895 million yuan, accounting for 5.53% [1] - Over the past five days, the stock has experienced fluctuations in fund flows, with notable net outflows from speculative funds on October 30 [1][2] Financing and Margin Trading - As of October 31, 2025, the financing balance was 1.05 billion yuan, with a net financing purchase of 1.5513 million yuan [2] - The margin trading balance stood at 1.06 billion yuan, with a short selling volume of 200 shares and a remaining short selling balance of 112.79 million yuan [1][2] Industry Comparison - Kefu Medical's total market value is 9.131 billion yuan, with a net asset value of 4.75 billion yuan, and a net profit of 260 million yuan, ranking 42nd, 29th, and 24th respectively in the medical device industry [4] - The company's price-to-earnings ratio (P/E) is 26.32, significantly lower than the industry average of 63.63, indicating a potentially undervalued position [4]
可孚医疗（301087）10月31日主力资金净买入201.72万元